Tisdag 13 Januari | 14:57:46 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-01-12 - Extra Bolagsstämma 2026
2025-08-28 - Kvartalsrapport 2025-Q2
2025-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2025-06-05 - Årsstämma
2025-04-10 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-06-19 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning CRNA 0.00 NOK
2024-04-25 - Bokslutskommuniké 2023
2023-10-04 - Split CRNA 30:1
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-22 - Årsstämma
2023-04-21 - X-dag ordinarie utdelning CRNA 0.00 NOK
2023-03-09 - Extra Bolagsstämma 2023
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-20 - Årsstämma
2022-04-07 - X-dag ordinarie utdelning CRNA 0.00 NOK
2022-02-17 - Bokslutskommuniké 2021
2021-11-25 - Extra Bolagsstämma 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1
2021-03-18 - X-dag ordinarie utdelning CRNA 0.00 NOK
2021-03-17 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-30 - X-dag ordinarie utdelning CRNA 0.00 NOK
2020-04-29 - Årsstämma
2020-03-11 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-09 - Kvartalsrapport 2019-Q1
2019-04-10 - X-dag ordinarie utdelning CRNA 0.00 NOK
2019-04-09 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-11-01 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-03 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning CRNA 0.00 NOK
2018-04-11 - Årsstämma
2018-02-15 - Bokslutskommuniké 2017
2017-11-16 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-05 - Årsstämma
2017-02-16 - Bokslutskommuniké 2016
2016-11-17 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-12 - Kvartalsrapport 2016-Q1
2016-04-14 - X-dag ordinarie utdelning CRNA 0.00 NOK
2016-04-13 - Årsstämma
2015-06-23 - X-dag ordinarie utdelning CRNA 0.00 NOK
2015-06-22 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-09 07:00:00

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 9 January 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA (the “Company”) on 8 December 2025 with key information relating to the contemplated 88% underwritten and presubscribed rights issue in the Company, raising gross proceeds of up to NOK 50 million (the “Rights Issue”).

Please see updated key information below:

  • Date on which the terms and conditions of the preferential rights issue were announced: 8 December 2025
  • Last day of trading including subscription rights: 12 January 2026
  • Ex-date: 13 January 2026
  • Record Date: 14 January 2026 (assuming normal T+2 settlement)
  • Date of approval of the Rights Issue: 12 January 2026 (extraordinary general meeting)
  • Maximum number of new shares: 50 million shares
  • Subscription price: NOK 1.00
  • Ratio preferential rights: Each existing shareholder as of 12 January 2026 (and being registered as such in Euronext Securities Oslo, the Norwegian Central Securities Depository (VPS) at the expiry of 14 January 2026 (the Record Date)) will be granted 0.3481 subscription rights for each share registered as held by the shareholder. The number of subscription rights granted to each existing shareholder will be rounded down to the nearest whole subscription right.
  • Subscription ratio: 1:1 (number of new shares per subscription right)
  • Manager: Vator Securities AB (the "Manager")
  • Will the rights be listed: Yes, the subscription rights will be listed on the Oslo Stock Exchange (ticker code: CRNAT)
  • ISIN for the subscription rights: ISIN NO 0013711515
  • Warrants: The subscribers in the Rights Issue will without additional consideration be allocated one warrant (Nw.: frittstående tegningsrett) (the "Warrants") issued by the Company for every new share subscribed for and allocated to the subscriber in the Rights Issue (the “Warrants”). The number of Warrants to be issued in the Rights Issue will be minimum 44,200,000 and maximum 50,000,000. Each Warrant will give the holder the right to subscribe for and be allocated one additional share in the Company at a subscription price equal to 80% of the volume-weighted average price of the Company's share on the Oslo Stock Exchange between 8 May 2026 – 22 May 2026, but not less than the nominal value of Company’s shares at the time of the exercise period and may be exercised in the period from 09:00 hours (CEST) on 26 May 2026 to 16:30 hours (CEST) on 9 June 2026 (the “Exercise Period”). The Company may apply for listing of the Warrants on the Oslo Stock Exchange or Euronext Growth Oslo.
  • ISIN for the Warrants: ISIN NO 0013711523
  • Other information: Reference is made to the stock exchange announcement published by the Company on 8 December 2025, for further information regarding the Rights Issue. The Rights Issue is subject to (i) approval by the extraordinary general meeting to be held on 12 January 2026 and (ii) publication of a prospectus for the offering and listing of the new shares and warrants as approved by the Financial Supervisory Authority of Norway.

This information is published in accordance with the requirements of the Continuing Obligations.